Need professional-grade analysis? Visit stockanalysis.com
$10.58M
N/A
N/A
N/A
Price Chart
Risk-Adjusted Performance
Nymox Pharmaceutical Corporation (NYMXF) Price Performance
Nymox Pharmaceutical Corporation (NYMXF) trades on United States in USD. The company is classified in the Healthcare sector under the In Vitro & In Vivo Diagnostic Substances industry. The stock currently trades at $0.07, down 37.05% from the previous close.
Over the past year, NYMXF has traded between a low of $0.04 and a high of $0.15. The stock has lost 22.4% over this period. It is currently 52.8% below its 52-week high.
Nymox Pharmaceutical Corporation has a market capitalization of $10.58M.
About Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert, a test for determining smoking status; and TobacAlert, a test for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment and prevention of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.
Company Info
- Sector
- Healthcare
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- N/A
- EBITDA
- $-4,282,000
- Profit Margin
- N/A
- EPS (TTM)
- -0.05
- Book Value
- -0.07
Technical Indicators
- 52 Week High
- $0.15
- 52 Week Low
- $0.03
- 50 Day MA
- $0.05
- 200 Day MA
- $0.07
- Beta
- 14.63
Valuation
- Trailing P/E
- N/A
- Forward P/E
- N/A
- Price/Sales
- N/A
- Price/Book
- -1.55
- Enterprise Value
- $13.80M